Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Neuro-Oncology|March 23, 2013
Secondary hematological malignancies associated with temozolomide in patients with gliomaHiroyuki Momota, Yoshitaka Narita, Yasuji Miyakita, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|September 10, 2015
The necessity of long-term follow-up including spinal examination after successful initial treatment of intracranial germinoma: case reportsMakoto Ohno, Yoshitaka Narita, Yasuji Miyakita, et al.
Nagoya Journal of Medical Science|October 25, 2012
Intravascular lymphoma of the central nervous system presenting as multiple cerebral infarctionsHiroyuki Momota, Yoshitaka Narita, Yasuji Miyakita, et al.
No Shinkei Geka. Neurological Surgery|May 8, 2002
[A case of traumatic chiasmal syndrome presenting with bitemporal upper quadrantanopsia]Yasuji Miyakita, Yoshio Taguchi, Motoshi Matsuzawa, et al.
Brain Tumor Pathology|November 4, 2010
p53 abnormality and tumor invasion in patients with malignant astrocytomaHiroyuki Momota, Yoshitaka Narita, Yuko Matsushita, et al.
No Shinkei Geka. Neurological Surgery|November 4, 2009
[A survey of neurosurgeons' policies and attitudes regarding the disclosure of a diagnosis of glioma and the decision to pursue end-of-life care in glioma patients]Yoshitaka Narita, Yasuji Miyakita, Hiroyuki Momota, et al.
Japanese Journal of Clinical Oncology|March 5, 2020
Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphomaYasuji Miyakita, Makoto Ohno, Masamichi Takahashi, et al.
Cancer Medicine|February 22, 2023
A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasisYu Toda, Eisuke Kobayashi, Daisuke Kubota, et al.
Japanese Journal of Clinical Oncology|October 6, 2017
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL)Yasuji Miyakita, Makoto Ohno, Masamichi Takahashi, et al.
Japanese Journal of Clinical Oncology|July 20, 2022
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastomaMakoto Ohno, Yasuji Miyakita, Masamichi Takahashi, et al.
Pageof 9